glimepiride · Amaryl

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (33)
Type 2 Diabetes
NCT07288749 · Tongji Hospital
2026-01-01 – 2031-12-31 · Type 2 Diabetes Mellitus (T2DM), Chronic Heart Failure (CHF)
What this study did
NCT04841096 · Laboratorios Silanes S.A. de C.V.
2023-03-21 – 2024-05-15 · Type 2 Diabetes
What this study did
NCT01794143 · GRADE Study Group
2013-05 – 2021-04-30 · Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
What this study did
NCT02769481 · Theracos
2016-08-15 – 2019-06-14 · Type 2 Diabetes Mellitus
What this study did
NCT03060980 · Intarcia Therapeutics
2017-03-03 – 2018-01-26 · Diabetes Mellitus, Type 2
What this study did
NCT02099110 · Merck Sharp & Dohme LLC
2014-04-22 – 2016-05-26 · Type 2 Diabetes Mellitus
What this study did
NCT01699932 · Sanofi
2012-09 – 2014-04 · Type 2 Diabetes Mellitus
What this study did
NCT01459809 · Sanofi
2012-02 – 2014-01 · Diabetes Mellitus, Type 2
What this study did
NCT01457911 · Sanofi
2011-10 – 2013-02 · Type 2 Diabetes Mellitus
What this study did
NCT01075282 · Eli Lilly and Company
2010-02 – 2012-11 · Diabetes Mellitus, Type 2
What this study did
NCT01296412 · Merck Sharp & Dohme LLC
2011-03-11 – 2012-02-29 · Diabetes Mellitus, Type 2
What this study did
NCT01076075 · Merck Sharp & Dohme LLC
2010-06-03 – 2012-01-19 · Type 2 Diabetes Mellitus
What this study did
NCT00151697 · Rijnstate Hospital
started 2005-05 · Diabetes Mellitus Type II
What this study did
NCT00947557 · Forest Laboratories
2009-07 – 2010-07 · Diabetes Mellitus, Type II
What this study did
NCT00614120 · Novo Nordisk A/S
2008-01 – 2009-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00770952 · Takeda
2006-12 – 2008-12 · Diabetes Mellitus
What this study did
NCT00032487 · VA Office of Research and Development
2000-12-01 – 2008-05-30 · Type 2 Diabetes Mellitus
What this study did
NCT00427154 · Novo Nordisk A/S
2007-01-10 – 2008-03-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00343980 · Novo Nordisk A/S
2006-10-10 – 2008-03-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00131664 · Canadian Heart Research Centre
2005-09 – 2008-01 · Type 2 Diabetes Mellitus
What this study did
NCT00437554 · Handok Inc.
2006-08 – 2007-07 · Diabetes Mellitus, Type 2
What this study did
NCT00318422 · Novo Nordisk A/S
2006-05 – 2007-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00331851 · Novo Nordisk A/S
2006-05 – 2007-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00353691 · Sanofi
2002-10 – 2004-11 · Type 2 Diabetes Mellitus
What this study did
NCT00783744 · Sanofi
2001-12 – 2003-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT02484209 · Diabetes Frail Ltd
2016-02 – 2016-11 · Diabetes Mellitus
What this study did
Phase 2/3 (2)
Type 2 Diabetes
NCT01318135 · Takeda
2009-01 – 2010-04 · Type 2 Diabetes Mellitus
What this study did
NCT01318083 · Takeda
2008-08 – 2009-04 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (1)
Type 2 Diabetes
NCT01425580 · Thomas Nystrom
2012-01 – 2016-08 · Congestive Heart Failure, Type 2 Diabetes Mellitus
What this study did
Phase 1 (17)
Type 2 Diabetes
NCT02954822 · Dong-A ST Co., Ltd.
2016-11-14 – 2017-08-09 · Type2 Diabetes
What this study did
NCT01614769 · Merck Sharp & Dohme LLC
2012-07-18 – 2013-01-23 · Type 2 Diabetes Mellitus
What this study did
NCT00842556 · AstraZeneca
2009-03 – 2009-05 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT03009513 · Handok Inc.
2017-01 – 2017-06 · Diabetes Mellitus
What this study did
NCT01768455 · LG Life Sciences
2013-02 – 2013-04 · Healthy
What this study did
NCT01496443 · Takeda
2012-01 – 2012-05 · Pharmacokinetics
What this study did
NCT01437813 · Laboratorios Silanes S.A. de C.V.
2011-01 – 2011-03 · Healthy
What this study did
NCT01437800 · Laboratorios Silanes S.A. de C.V.
2011-01 – 2011-03 · Healthy
What this study did
NCT01133431 · Chong Kun Dang Pharmaceutical
2010-05 – 2010-08 · Healthy Male Volunteer
What this study did
NCT01302158 · Astellas Pharma Inc
2009-12 – 2010-04 · Healthy Subjects
What this study did
NCT02172261 · Boehringer Ingelheim
2009-04 – 2009-06 · Healthy
What this study did
NCT00934323 · Handok Inc.
2008-10 – 2009-04 · Healthy
What this study did
NCT00934817 · Handok Inc.
2007-03 – 2007-08 · Healthy
What this study did
NCT01052909 · Dr. Reddy's Laboratories Limited
2003-12 – 2003-12 · Healthy
What this study did
NCT01053689 · Dr. Reddy's Laboratories Limited
2003-12 – 2003-12 · Healthy
What this study did
Phase 4 (40)
Type 2 Diabetes
NCT06759922 · Bahria University
2025-01-01 – 2025-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT05386186 · Peking University People's Hospital
2022-01-01 – 2024-03-31 · Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes
What this study did
NCT04528212 · Rehab Werida
2020-11-01 – 2021-12-01 · Diabetes Mellitus, Type 2
What this study did
NCT04470310 · Seoul National University Hospital
2015-12-31 – 2021-08-31 · Type 2 Diabetes Mellitus
What this study did
NCT02649465 · Kanazawa University
2015-11-11 – 2021-06-30 · Non-alcoholic Fatty Liver Disease
What this study did
NCT04287387 · Peking Union Medical College Hospital
2020-03-02 – 2021-03-02 · Type2 Diabetes Mellitus
What this study did
NCT03693560 · Damanhour University
2018-10-08 – 2019-10-10 · Coronary Artery Disease, Diabetes Mellitus, Type 2
What this study did
NCT02973477 · University of Michigan
2017-01-12 – 2019-08-22 · Type2 Diabetes, Cardiovascular Diseases
What this study did
NCT03118713 · Astellas Pharma Korea, Inc.
2017-04-25 – 2018-12-12 · Type 2 Diabetes Mellitus
What this study did
NCT02280486 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2015-01 – 2017-10 · Type 2 Diabetes
What this study did
NCT04237493 · University of Jordan
2017-02-14 – 2017-07-24 · Diabetes Mellitus, Type 2
What this study did
NCT02471404 · AstraZeneca
2015-09-21 – 2017-03-13 · Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
What this study did
NCT02142309 · University of Campania Luigi Vanvitelli
2005-10 – 2017-01 · Type 2 Diabetes
What this study did
NCT02007278 · Novartis Pharmaceuticals
2014-01-03 – 2016-02-22 · Type 2 Diabetes, Hypoglycemia
What this study did
NCT01812122 · Seoul National University Hospital
2013-03 – 2015-10 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
NCT01890629 · LG Life Sciences
2013-05 – 2014-08 · Type 2 Diabetes Mellitus
What this study did
NCT00858013 · Ajou University School of Medicine
2009-04-24 – 2014-06-25 · Type 2 Diabetes Mellitus
What this study did
NCT01341717 · Jothydev's Diabetes and Research Centre
2012-02 – 2014-05 · Diabetes Mellitus, Type 2
What this study did
NCT01660386 · Shanghai Jiao Tong University School of Medicine
2012-07 – 2013-03 · Type 2 Diabetes
What this study did
NCT00949442 · Sanofi
2009-07 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01444248 · Handok Inc.
2010-08 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT01509001 · University of Sao Paulo
2011-01 – 2012-01 · Type 2 Diabetes
What this study did
NCT01144728 · Sanofi
2010-05 – 2010-12 · Diabetes Mellitus, Type 2
What this study did
NCT00913367 · Handok Inc.
2009-05 – 2010-11 · Type 2 Diabetes Mellitus
What this study did
NCT00957060 · Sanofi
2009-07 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT00908921 · Sanofi
2009-04 – 2010-09 · Diabetes Mellitus, Type 2
What this study did
NCT00941161 · Laboratorios Silanes S.A. de C.V.
2009-02 – 2010-05 · Type 2 Diabetes Mellitus
What this study did
NCT00708578 · Sanofi
2008-05 – 2009-12 · Type 2 Diabetes Mellitus
What this study did
NCT00612144 · Handok Inc.
2007-12 – 2009-05 · Type 2 Diabetes Mellitus
What this study did
NCT00360698 · Sanofi
2006-07 – 2008-08 · Diabetes Mellitus, Type 2
What this study did
NCT00469092 · Novo Nordisk A/S
2007-05 – 2008-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01429818 · Laboratorios Silanes S.A. de C.V.
2007-07 – 2008-01 · Endothelial Dysfunction, Diabetes Mellitus
What this study did
NCT00318656 · GlaxoSmithKline
2005-11 – 2007-10 · Non-Insulin-Dependent Diabetes Mellitus
What this study did
NCT00576784 · IKFE Institute for Clinical Research and Development
2005-04 – 2007-04 · Type 2 Diabetes Mellitus, Insulin Resistance
What this study did
NCT00619697 · Novo Nordisk A/S
2003-12 – 2005-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT02528019 · Kurume University
2015-08 – 2018-08 · Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
What this study did
NCT00642915 · Sanofi
2003-06 – 2004-07 · Diabetes Mellitus
What this study did
Early phase / not applicable (12)
Type 2 Diabetes
NCT03907423 · Rehab Werida
2019-04-01 – 2021-01-31 · Diabetes Mellitus, Type 2
What this study did
NCT02443922 · Foundation for the National Institutes of Health
2015-06 – 2015-12 · Type 2 Diabetes
What this study did
NCT02026310 · Qifu Li
2014-01 – 2015-12 · Diabetes Mellitus, Type 2
What this study did
NCT01561976 · GlaxoSmithKline
2012-01-30 – 2012-02-21 · Diabetes Mellitus, Type 2
What this study did
NCT00608179 · Vanderbilt University
2002-08 – 2010-12 · Type 2 Diabetes
What this study did
NCT00747383 · The Royal Bournemouth Hospital
2008-09 – 2010-09 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07589387 · Washington University School of Medicine
2026-02-14 – 2030-01-31 · Diabete Mellitus
What this study did
NCT00679237 · Sorlandet Hospital HF
2007-09 – 2019-12 · Coronary Heart Disease
What this study did
NCT03081676 · University Hospital, Gentofte, Copenhagen
2017-03-08 – 2018-06-01 · Maturity-Onset Diabetes of the Young, Type 3
What this study did
NCT01819402 · Kurume University
2012-03 – 2013-04 · To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
What this study did
NCT00776620 · Ranbaxy Laboratories Limited
2003-07 – 2003-09 · Healthy
What this study did
NCT00776490 · Ranbaxy Laboratories Limited
2003-07 – 2003-09 · Healthy
What this study did
Used as active comparator (87)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (32)
Type 2 Diabetes
NCT03332771 · Lexicon Pharmaceuticals
2017-12-01 – 2019-09-06 · Type 2 Diabetes Mellitus
What this study did
NCT01243424 · Boehringer Ingelheim
2010-11-11 – 2018-08-21 · Diabetes Mellitus, Type 2
What this study did
NCT02033889 · Merck Sharp & Dohme LLC
2013-12-13 – 2017-08-03 · Type 2 Diabetes Mellitus
What this study did
NCT01167881 · Boehringer Ingelheim
2010-08 – 2015-08 · Diabetes Mellitus, Type 2
What this study did
NCT01644500 · Eli Lilly and Company
2012-07 – 2014-08 · Type 2 Diabetes Mellitus
What this study did
NCT01455922 · Intarcia Therapeutics
2013-02 – 2014-07 · Type 2 Diabetes
What this study did
NCT01455883 · Intarcia Therapeutics
2013-02 – 2014-07 · Type 2 Diabetes
What this study did
NCT01481116 · Takeda
2012-01 – 2014-04 · Diabetes Mellitus, Type 2
What this study did
NCT00838903 · GlaxoSmithKline
2009-02 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT00968812 · Janssen Research & Development, LLC
2009-09 – 2013-01 · Diabetes Mellitus, Type 2
What this study did
NCT01477853 · Merck Sharp & Dohme LLC
2011-10-24 – 2012-12-04 · Type 2 Diabetes Mellitus
What this study did
NCT01189890 · Merck Sharp & Dohme LLC
2010-08-16 – 2012-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT01087502 · Boehringer Ingelheim
2010-03 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT00359762 · AstraZeneca
2006-09 – 2011-03 · Type 2 Diabetes Mellitus
What this study did
NCT01262586 · Novartis Pharmaceuticals
2010-11 – 2011-03 · Type II Diabetes Mellitus
What this study did
NCT00622284 · Boehringer Ingelheim
2008-02 – 2010-12 · Diabetes Mellitus, Type 2
What this study did
NCT01453049 · GlaxoSmithKline
2010-04 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT00620282 · Novo Nordisk A/S
2008-02 – 2010-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00701090 · Merck Sharp & Dohme LLC
2008-05 – 2009-10 · Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
What this study did
NCT00770653 · Takeda
2007-04 – 2009-05 · Diabetes Mellitus, Dyslipidemias
What this study did
NCT00449605 · Sanofi
2007-03 – 2009-03 · Diabetes Mellitus, Type 2
What this study did
NCT00294723 · Novo Nordisk A/S
2006-02 – 2008-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00106340 · Novartis Pharmaceuticals
2005-03 – 2008-05-20 · Diabetes Mellitus, Type 2
What this study did
NCT00469586 · Novo Nordisk A/S
2007-04-26 – 2008-04-24 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01585792 · Takeda
2012-05 – 2012-12 · Diabetic Patients
What this study did
NCT00225264 · Takeda
2003-10 – 2006-05 · Diabetes Mellitus
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT01610934 · University Hospital, Gentofte, Copenhagen
2012-08 – 2013-08 · Maturity-onset Diabetes of the Young
What this study did
Phase 2 (8)
Type 2 Diabetes
NCT01699737 · Akros Pharma Inc.
2012-09 – 2013-07 · Type 2 Diabetes Mellitus
What this study did
NCT01408095 · Eli Lilly and Company
2011-09 – 2012-09 · Diabetes Mellitus, Type 2
What this study did
NCT01007097 · Takeda
2009-12 – 2010-09 · Diabetes Mellitus, Type 2
What this study did
NCT00792935 · Merck Sharp & Dohme LLC
2009-01 – 2010-02 · Type 2 Diabetes Mellitus
What this study did
NCT00309608 · Boehringer Ingelheim
2006-04 – 2007-08 · Diabetes Mellitus, Type 2
What this study did
NCT01509755 · Novo Nordisk A/S
2000-10 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 1 (7)
Type 2 Diabetes
NCT00562250 · AstraZeneca
2008-05 – 2008-08 · Diabetes Mellitus, Type 2
What this study did
NCT01511692 · Novo Nordisk A/S
2005-11 – 2007-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00650533 · Mylan Pharmaceuticals Inc
2004-11 – 2004-12 · Healthy
What this study did
NCT00648362 · Mylan Pharmaceuticals Inc
2004-11 – 2004-12 · Healthy
What this study did
NCT00834340 · Teva Pharmaceuticals USA
2003-02 – 2003-03 · Healthy
What this study did
NCT00835172 · Teva Pharmaceuticals USA
2003-03 – 2003-03 · Healthy
What this study did
Phase 4 (29)
Type 2 Diabetes
NCT07365358 · Chong Kun Dang Pharmaceutical
2026-03 – 2027-08 · Diabete Type 2
What this study did
NCT05975528 · Yonsei University
2023-06-01 – 2025-12-31 · Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
What this study did
NCT05663736 · Seoul National University Bundang Hospital
2020-01-01 – 2023-12-31 · Ejection Fraction
What this study did
NCT04183868 · University of Catanzaro
2016-04 – 2021-10 · Type 2 Diabetes, Cardiovascular Risk Factor
What this study did
NCT02919059 · IInstituto Gallego de Medicina Vascular
2016-12-13 – 2019-08 · Diabetes Mellitus, Type 2
What this study did
NCT02694263 · University of Leicester
2016-07 – 2018-09-13 · Diabetes Mellitus, Type 2
What this study did
NCT02985242 · Hannover Medical School
2017-06-12 – 2018-08-16 · Diabetes Mellitus, Type II
What this study did
NCT02564926 · AstraZeneca
2016-01-05 – 2018-01-15 · Diabetes Mellitus, Type 2
What this study did
NCT02728453 · Hannover Medical School
2016-04-27 – 2017-09-27 · Diabetes Mellitus Type 2
What this study did
NCT02301806 · Dokkyo Medical University
2015-01 – 2017-07 · Type 2 Diabetes
What this study did
NCT02373865 · GWT-TUD GmbH
2015-09 – 2017-01 · Diabetes Mellitus Type 2
What this study did
NCT02426294 · Pusan National University Hospital
2015-02 – 2016-05 · Type 2 Diabetes Mellitus
What this study did
NCT02312063 · Kansai Electric Power Hospital
2015-02 – 2016-05 · Diabetes Mellitus, Type 2
What this study did
NCT02106104 · Amsterdam UMC, location VUmc
2014-03 – 2016-04 · Type 2 Diabetes
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT01910441 · Novartis Pharmaceuticals
2013-07 – 2014-09 · Type 2 Diabetes Mellitus
What this study did
NCT00993187 · Merck Sharp & Dohme LLC
2010-05-04 – 2013-10-29 · Type 2 Diabetes Mellitus
What this study did
NCT00474838 · Kyunghee University Medical Center
2007-04 – 2012-12 · Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity
What this study did
NCT01006603 · AstraZeneca
2009-10 – 2012-06 · Type 2 Diabetes Mellitus
What this study did
NCT00939939 · Ludwig-Maximilians - University of Munich
2010-03 – 2011-05 · Diabetes Mellitus Type 2
What this study did
NCT00562172 · Sanofi
2007-09 – 2010-10 · Type 2 Diabetes Mellitus
What this study did
NCT00699322 · The Catholic University of Korea
2008-06 – 2010-06 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT02823808 · Kyunghee University Medical Center
2017-07 – 2021-12 · Diabetes
What this study did
NCT02462369 · The Second Hospital of Nanjing Medical University
2015-06 – 2017-10 · Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR
What this study did
Early phase / not applicable (10)
Type 2 Diabetes
NCT06068686 · Damanhour University
2022-10-01 – 2024-12-01 · Type 2 Diabetes
What this study did
NCT01951339 · University of Colorado, Denver
2013-10 – 2018-06 · Type 2 Diabetes, Cardiovascular Disease
What this study did
NCT02964572 · Yonsei University
2016-11 – 2017-07 · Type2 Diabetes Mellitus
What this study did
NCT01183104 · Japan Association for Diabetes Education and Care
2010-08 – 2015-01 · Type 2 Diabetes
What this study did
NCT00775684 · University of Pennsylvania
2008-10 – 2012-11 · Pre-diabetes, Type 2 Diabetes
What this study did
NCT00722631 · Kurume University
2007-05 – 2012-04 · Impaired Glucose Tolerance, Type 2 Diabetes Mellitus, Atherosclerosis
What this study did
Other / comorbidity
NCT02609815 · Seoul National University Bundang Hospital
2015-11-01 – 2021-03-15 · Diabetes
What this study did
NCT05468879 · PT Harsen Laboratories
2020-09-21 – 2021-01-06 · Drug Use
What this study did
NCT03917940 · Damanhour University
2019-01-31 – 2020-05-10 · Diabetic Patients
What this study did
NCT01677247 · Dexa Medica Group
2011-02 – 2011-03 · Glimepiride BE Study in Healthy Volunteers Under Fasting Condition
What this study did
Appears in other studies (15)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (14)
Type 2 Diabetes
NCT02630706 · Merck Sharp & Dohme LLC
2015-12-16 – 2017-12-27 · Type 2 Diabetes Mellitus
What this study did
NCT01717313 · Merck Sharp & Dohme LLC
2012-12-05 – 2015-06-19 · Type 2 Diabetes Mellitus
What this study did
NCT01769378 · Eli Lilly and Company
2013-01 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01829477 · Takeda
2013-04 – 2014-02 · Diabetes Mellitus, Type 2
What this study did
NCT01494987 · Gilead Sciences
2012-01 – 2013-08 · Type 2 Diabetes Mellitus
What this study did
NCT00839527 · GlaxoSmithKline
2009-02 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01177384 · Merck Sharp & Dohme LLC
2011-01-25 – 2013-03-25 · Type 2 Diabetes Mellitus
What this study did
NCT00680745 · AstraZeneca
2008-04 – 2010-05 · Type 2 Diabetes
What this study did
NCT00924573 · Sanofi
2009-05 – 2010-03 · Type 2 Diabetes Mellitus
What this study did
NCT00099944 · Novartis Pharmaceuticals
2004-05 – 2005-10 · Diabetes Mellitus, Type 2
What this study did
Phase 1 (1)
Type 2 Diabetes
NCT02956044 · Theracos
2016-11 – 2017-03 · Type2 Diabetes Mellitus
What this study did

Competitive landscape

Other Sulfonylurea receptor (SUR1) drugs

Glipizide, Glyburide. Compare all 3 Sulfonylurea receptor (SUR1) drugs

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Glimepiride (Amaryl): this drugApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 88 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Amaryl (glimepiride) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
April 2029 (1)
Early phase / not applicableDiabete MellitusRecruiting
Est. primary completion 2029-04-30 · NCT07589387 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3Type 2 DiabetesNot yet recruiting
Est. primary completion 2030-12-31 · NCT07288749 · CT.gov ↗
What to watch

See the full readout calendar ↗